Cargando…

Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report

BACKGROUND: Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin’s lymphoma. Standard first-line treatment for this aggressive subtype comprises the anti-CD20 antibody rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone. If patients receiving such tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jurczak, Wojciech, Bryk, Agata Hanna, Mensah, Patrycja, Gałązka, Krystyna, Trofimiuk–Müldner, Małgorzata, Wyrobek, Łukasz, Sawiec, Anna, Skotnicki, Aleksander B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868005/ https://www.ncbi.nlm.nih.gov/pubmed/27178351 http://dx.doi.org/10.1186/s13256-016-0875-x

Ejemplares similares

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma
por: Jurczak, W, et al.
Publicado: (2018)

Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report
por: Krawczyk, Katarzyna, et al.
Publicado: (2014)

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
por: Duell, Johannes, et al.
Publicado: (2021)

Salvage treatment of relapsed/refractory LCH
por: Seo, Jong Jin
Publicado: (2016)

Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi
por: Kaimila, Bongani, et al.
Publicado: (2017)

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
por: Choi, Chul Won, et al.
Publicado: (2002)

The development of guidelines for management of thyroid diseases in pregnancy – current status
por: Hubalewska-Dydejczyk, Alicja, et al.
Publicado: (2015)

Update on Salvage Options in Relapsed/Refractory Hodgkin Lymphoma after Autotransplant
por: Iqbal, Nida, et al.
Publicado: (2014)

Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
por: Thumallapally, Nishitha, et al.
Publicado: (2016)

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
por: Popescu, Bogdan, et al.
Publicado: (2019)

P1079: COMPARISON OF NOVEL SALVAGE REGIMENS AND TRADITIONAL SALVAGE CHEMOTHERAPY IN RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
por: Ermann, D., et al.
Publicado: (2022)

P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma
por: Shah, Harsh, et al.
Publicado: (2022)

Efficacy of salvage radiotherapy for relapsed/refractory diffuse large B-cell lymphoma
por: Wang, Shu-Bei, et al.
Publicado: (2019)

Zacualpan, Mor. : un estudio de relaciones sociales
por: Ramírez Melgarejo, Ramón
Publicado: (1976)

AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors
por: Wang, Chang-Lu, et al.
Publicado: (2022)

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
por: Salles, Gilles, et al.
Publicado: (2021)

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
por: Stadtmauer, Edward A, et al.
Publicado: (2009)

Treating second‐relapsed/refractory first‐relapsed childhood acute myeloid leukaemia: Successful salvage rather than palliation?
por: Merli, Pietro
Publicado: (2022)

Mors repentina, ensayos sobre la grandeza y la miseria del cuerpo /
por: González-Crussí, F.
Publicado: (2001)

Decitabine salvage for TP53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy
por: Ferraro, Francesca, et al.
Publicado: (2022)

Theoretical Study for Adsorption–Diffusion on H-MOR and Pyridine Pre-adsorbed H-MOR of Dimethyl Ether Carbonylation
por: Zhao, Jiabao, et al.
Publicado: (2023)

The average relative dose intensity of R‐CHOP is an independent factor determining favorable overall survival in diffuse large B‐cell lymphoma patients
por: Długosz‐Danecka, Monika, et al.
Publicado: (2019)

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma
por: Ng, M, et al.
Publicado: (2005)

ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkin's Lymphoma: A Single Center Experience
por: Park, Sang Hyoung, et al.
Publicado: (2006)

Fludarabine-based salvage therapy for refractory/relapsed acute leukemias: A single center experience
por: Abbasi, Abdul Muqtadir, et al.
Publicado: (2021)

Hypomethylating Agents (HMAs) as Salvage Therapy in Relapsed or Refractory AML: An Italian Multicentric Retrospective Study
por: Lessi, Federica, et al.
Publicado: (2021)

Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults
por: Ju, Hee Young, et al.
Publicado: (2022)

Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy
por: Mühleck, Regina, et al.
Publicado: (2021)

PB2263: TOXICITY PROFILE OF SALVAGE CHEMOTHERAPY REGIMENS IN PATIENTS WITH RELAPSED/ REFRACTORY HODGKIN LYMPHOMA.
por: Zahra, Kmira, et al.
Publicado: (2023)

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience
por: Stefoni, Vittorio, et al.
Publicado: (2022)

Pseudomonas aeruginosa Uses c-di-GMP Phosphodiesterases RmcA and MorA To Regulate Biofilm Maintenance
por: Katharios-Lanwermeyer, S., et al.
Publicado: (2021)

Role of efficacy as a determinant of locomotor activation by mu‐opioid receptor (MOR) ligands in female and male mice. II. Effects of novel MOR‐selective phenylmorphans with high‐to‐low MOR efficacy
por: Santos, Edna J., et al.
Publicado: (2023)

Modifier Role of Common RET Variants in Sporadic Medullary Thyroid Carcinoma
por: Skalniak, Anna, et al.
Publicado: (2021)

FRI491 The Impact Of Insulin Resistance On Thyroid Function In Pregnancy
por: Trofimiuk-Muldner, Malgorzata, et al.
Publicado: (2023)

FRI489 The Interplay Between Thyroid Nodular Disease And Insulin Resistance Indices In Pregnant Women
por: Jerzy Nowak, Andrzej, et al.
Publicado: (2023)

Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience
por: da Silva, Wellington Fernandes, et al.
Publicado: (2020)

Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease
por: Abdallah, Al‐Ola, et al.
Publicado: (2021)

Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy
por: Ababneh, Hazim S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ppdqlruq29ge3johdsoc5d2qgj